The epigenetic EZH2/H3K27me3 axis modulates lactotroph tumor cell proliferation.
EZH2
GSK343
H3K27me3
PRL tumor
Journal
The Journal of endocrinology
ISSN: 1479-6805
Titre abrégé: J Endocrinol
Pays: England
ID NLM: 0375363
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
17
01
2023
accepted:
10
02
2023
medline:
31
3
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
epublish
Résumé
Interest in epigenetics has gained substantial momentum as a result of their identified role in the regulation of tumor progression as well as their ability to pharmacologically target genes. Pituitary neuroendocrine tumors (PitNETs) tend to be inactivated via epigenetic modification, and although emerging evidence has suggested a role for epigenetic factors in PitNET tumorigenesis, the degree to which these factors may be targeted by new therapeutic strategies still remains poorly understood. The objective of the present study was to examine the participation of the EZH2/H3K27me3 axis in the proliferation of lactotroph tumor cells. We demonstrated that the levels of EZH2 and H3K27me3 were increased in murine experimental prolactin (PRL) tumors with respect to a control pituitary, in contrast with the low p21 mRNA levels encountered, with an H3K27me3 enrichment being observed in its promoter region in a GH3 tumor cell. Furthermore, specific EZH2/H3K27me3 axis inhibition blocked the proliferation of primary tumor cell culture and GH3 cells, thereby making it an attractive therapeutic target for PRL PitNETs.
Identifiants
pubmed: 36786578
doi: 10.1530/JOE-22-0195
pii: JOE-22-0195
doi:
pii:
Substances chimiques
Histones
0
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
EZH2 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM